BIOVIE INC (BIVI) Stock Fundamental Analysis

NASDAQ:BIVI • US09074F5044

1.38 USD
+0.11 (+8.66%)
At close: Feb 27, 2026
1.3999 USD
+0.02 (+1.44%)
After Hours: 2/27/2026, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, BIVI scores 3 out of 10 in our fundamental rating. BIVI was compared to 520 industry peers in the Biotechnology industry. The financial health of BIVI is average, but there are quite some concerns on its profitability. BIVI is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BIVI has reported negative net income.
  • In the past year BIVI has reported a negative cash flow from operations.
  • In the past 5 years BIVI always reported negative net income.
  • BIVI had a negative operating cash flow in each of the past 5 years.
BIVI Yearly Net Income VS EBIT VS OCF VS FCFBIVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • BIVI's Return On Assets of -77.67% is on the low side compared to the rest of the industry. BIVI is outperformed by 65.33% of its industry peers.
  • BIVI has a Return On Equity (-90.72%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -77.67%
ROE -90.72%
ROIC N/A
ROA(3y)-119.07%
ROA(5y)-705.14%
ROE(3y)-211.57%
ROE(5y)-997.19%
ROIC(3y)N/A
ROIC(5y)N/A
BIVI Yearly ROA, ROE, ROICBIVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • BIVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIVI Yearly Profit, Operating, Gross MarginsBIVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for BIVI has been increased compared to 1 year ago.
  • BIVI has more shares outstanding than it did 5 years ago.
  • BIVI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BIVI Yearly Shares OutstandingBIVI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BIVI Yearly Total Debt VS Total AssetsBIVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -22.25, we must say that BIVI is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BIVI (-22.25) is worse than 84.29% of its industry peers.
  • BIVI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.25
ROIC/WACCN/A
WACCN/A
BIVI Yearly LT Debt VS Equity VS FCFBIVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M -20M -30M -40M

2.3 Liquidity

  • A Current Ratio of 7.25 indicates that BIVI has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 7.25, BIVI is in the better half of the industry, outperforming 70.50% of the companies in the same industry.
  • BIVI has a Quick Ratio of 7.25. This indicates that BIVI is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.25, BIVI is in the better half of the industry, outperforming 70.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.25
Quick Ratio 7.25
BIVI Yearly Current Assets VS Current LiabilitesBIVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 87.03% over the past year.
EPS 1Y (TTM)87.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 60.24% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.11%
EPS Next 2Y72.68%
EPS Next 3Y69.51%
EPS Next 5Y60.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIVI Yearly Revenue VS EstimatesBIVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 2032 50M 100M 150M 200M 250M
BIVI Yearly EPS VS EstimatesBIVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600

4

4. Valuation

4.1 Price/Earnings Ratio

  • BIVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 0.31, which indicates a rather cheap valuation of BIVI.
  • Based on the Price/Forward Earnings ratio, BIVI is valued cheaper than 99.81% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. BIVI is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 0.31
BIVI Price Earnings VS Forward Price EarningsBIVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIVI Per share dataBIVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • BIVI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as BIVI's earnings are expected to grow with 69.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.68%
EPS Next 3Y69.51%

0

5. Dividend

5.1 Amount

  • BIVI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

BIOVIE INC

NASDAQ:BIVI (2/27/2026, 8:00:02 PM)

After market: 1.3999 +0.02 (+1.44%)

1.38

+0.11 (+8.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)05-11
Inst Owners17.94%
Inst Owner Change8.84%
Ins Owners0.24%
Ins Owner Change0%
Market Cap10.41M
Revenue(TTM)N/A
Net Income(TTM)-17.48M
Analysts82.86
Price Target12.24 (786.96%)
Short Float %2.59%
Short Ratio1.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-80%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-391.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.31
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-5.13
EYN/A
EPS(NY)4.42
Fwd EY320.04%
FCF(TTM)-1.9
FCFYN/A
OCF(TTM)-1.9
OCFYN/A
SpS0
BVpS2.56
TBVpS2.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -77.67%
ROE -90.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.07%
ROA(5y)-705.14%
ROE(3y)-211.57%
ROE(5y)-997.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.25
Quick Ratio 7.25
Altman-Z -22.25
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.17%
EPS Next Y33.11%
EPS Next 2Y72.68%
EPS Next 3Y69.51%
EPS Next 5Y60.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.16%
OCF growth 3YN/A
OCF growth 5YN/A

BIOVIE INC / BIVI FAQ

What is the fundamental rating for BIVI stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIVI.


Can you provide the valuation status for BIOVIE INC?

ChartMill assigns a valuation rating of 4 / 10 to BIOVIE INC (BIVI). This can be considered as Fairly Valued.


How profitable is BIOVIE INC (BIVI) stock?

BIOVIE INC (BIVI) has a profitability rating of 0 / 10.


What is the expected EPS growth for BIOVIE INC (BIVI) stock?

The Earnings per Share (EPS) of BIOVIE INC (BIVI) is expected to grow by 33.11% in the next year.